Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroalcoholic Elaeagnus angustifolia extract in mild to moderate benign prostatic hyperplasia
IRCT20150622022869N10Phase 3Completed
- Sponsor
- Yasouj University of Medical Sciences
- Start
- Oct 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of elaeagnus angustifolia extract in benign prostatic hyperplasia (BPH), sponsored by Yasouj University of Medical Sciences. Primary endpoints: Oxidative stress markers and Inflammatory markers. Started Oct 2022; status: completed.
02
Drugs
elaeagnus angustifolia extract
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20150622022869N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150622022869N10.